Key result
Radiotherapy plus pembrolizumab and lenvatinib yielded a partial response and >7 months progression-free survival in a patient with recurrent HCC and right atrium/inferior vena cava tumor thrombi.
Why the study?
The treatment of hepatocellular carcinoma with right atrium and inferior vena cava tumor thrombi is challenging, and a standard treatment is not well established.
Does radiotherapy plus pembrolizumab and lenvatinib improve outcomes in patients with recurrent HCC with RA and IVC tumor thrombi?
Case Report (n=1)
Does radiotherapy plus pembrolizumab and lenvatinib improve outcomes in patients with recurrent HCC with RA and IVC tumor thrombi?
Radiotherapy combined with pembrolizumab and lenvatinib may be a feasible and safe approach for treating recurrent hepatocellular carcinoma with right atrium and inferior vena cava tumor thrombi.
Background: The treatment of hepatocellular carcinoma (HCC) with right atrium (RA) and inferior vena cava (IVC) tumor thrombi is challenging, with the standard treatment being not well established. Immunotherapy plus antiangiogenic therapy is a potentially effective treatment for patients with advanced HCC. Here, we described the case of a patient with HCC with RA and IVC tumor thrombi who achieved a successful response from radiotherapy and targeted therapy plus immunotherapy. Case Summary: A 62-year-old women presented with severe bilateral lower extremity edema identified as recurrent HCC with RA and IVC tumor thrombi based on past medical history and computed tomography. The patient received palliative radiotherapy plus pembrolizumab and lenvatinib treatment and was relieved of disease symptoms of bilateral lower extremity edema. The HCC with RA and IVC tumor thrombi shrunk, and the progression-free survival of this patient was > seven months. Conclusion: Tumor thrombus-directed radiotherapy plus concurrent immunotherapy and targeted therapy might be a feasible and safe approach for patients with HCC with RA and IVC tumor thrombi.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2022) conducted a case report in Recurrent Hepatocellular Carcinoma with Right Atrium and Inferior Vena Cava Tumor Thrombus (n=1). Radiotherapy plus pembrolizumab and lenvatinib was evaluated on Progression-free survival and tumor response. Radiotherapy plus pembrolizumab and lenvatinib yielded a partial response and >7 months progression-free survival in a patient with recurrent HCC and right atrium/inferior vena cava tumor thrombi.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: